
David Johnson, Chairman and CEO of Enveric Biosciences
by Nick Opich on March 25, 2021 in podcast
Podcast: Play in new window | Download
by Nick Opich on March 25, 2021 in podcast
Podcast: Play in new window | Download
Podcast: Play in new window | Download
This week on The Green Rush, our hosts Nick and Anne are chatting with David Johnson, CEO of Enveric Biosciences, a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients.
It’s been a while since the Green Rush team has talked about CBD so we used this opportunity to get an update on the state of the space including how CBD is fitting into the existing medical landscape, the ways that technology is progressing the validation of these molecules and what the market could look like in the next several years. We also explore Enveric’s business model and how they compare to other players in the industry as well as key news from the industry including Jazz Pharmaceuticals acquisition of GW Pharma.
Now on to our conversation with David Johnson of Enveric Biosciences.
David Johnson, Chairman and CEO of Enveric Biosciences
Former CEO of Convatec, oversaw the $4.1B spin out of Convatec from Bristol Myers Squibb; former CEO of Alliqua Biomedical, a developer of wound care technologies.
Links and mentions in the show
Links to the guest’s company and social media accounts
Show Credits:
This episode was hosted by Anne Donohoe and Nick Opich of KCSA Strategic Communications.
Special thanks to our Program Director Shea Gunther.
You can learn more about how KCSA Cannabis can help your cannabiz by visiting www.kcsa-cannabis.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels:
Twitter: @The_GreenRush
Instagram: @thegreenrush_podcast
LinkedIn: https://www.linkedin.com/company/thegreenrushpodcast/
Facebook: https://www.facebook.com/TheGreenRushPodcast/
YouTube: https://www.youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true
Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture. This week Kris Kane and Anne Donohoe return for a new episode with special guest Frank Perullo, Co-Founder and Strategic Advisor at Ascend Wellness Holdings ($AAWH). Frank joins us this week […]
Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture. This week Lewis Goldberg and Anne Donohoe are back for a new episode with special guest Nathan Bryson, PhD, Chief Scientific Officer of Reunion Neuroscience. Nathan joins us this week to […]
Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture. This week Anne Donohoe and Phil Carlson return for a new episode with special guest Len May, CEO and Co-Founder of Endocanna Health. Len joins us this week to share how […]
Welcome to the Green Rush, a KCSA Strategic Communications Production, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets and culture. This week Anne Donohoe and Kris Krane are back for a new episode with special guest Adam Smith, Founder of Alliance for Sensible Markets. Adam joined us this week to talk […]